SCHEMBL2238865

SCHEMBL2238865

Cn1c(CC(N)=O)ccc1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.57
CXCL8 P10145 1/20 0.57
AKR1B1 P15121 1/20 0.57
PTGS1 P23219 1/20 0.57
GLO1 Q04760 1/20 0.57
HPGD P15428 2/20 0.55
HTT P42858 2/20 0.47
ABCB11 O95342 1/20 0.46
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HRH3 Q9Y5N1 4/20 0.42
BDKRB2 P30411 1/20 0.40
SRD5A2 P31213 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239972 0.87 PTGS2 (0.76) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL9724249 0.87 PTGS2 (0.76) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11814664 0.86 PTGS2 (0.48) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11807843 0.85 CXCL8 (0.60) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL8733799 0.83 PTGS2 (0.70) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11812863 0.83 PTGS2 (0.55) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11818395 0.83 HTT (0.41) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11810708 0.83 PTGS2 (0.55) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11810107 0.82 PTGS2 (0.51) PTGS2CXCL8AKR1B1PTGS1GLO1
SCHEMBL11811163 0.82 CXCL8 (0.53) PTGS2CXCL8AKR1B1PTGS1GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 US claimed
US-20110195967-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2011-08-11 US claimed
EP-1590314-B1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ FARMACEUTICI S P A (IT) 2015-08-05 EP disclosed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 US disclosed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 US disclosed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 US disclosed
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 US disclosed
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 US disclosed
US-8648110-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE PHA.R.MA S.P.A. (IT) 2014-02-11 US disclosed
US-20110195967-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2011-08-11 US disclosed
US-20110195967-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2011-08-11 US disclosed
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2010-10-21 US disclosed
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2010-10-21 US disclosed
US-7776909-B2 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPE PHA.R.MA S.P.A. (IT) 2010-08-17 US disclosed
US-7776909-B2 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPE PHA.R.MA S.P.A. (IT) 2010-08-17 US disclosed
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPÉ FARMACEUTICI S.P.A. (IT) 2006-10-05 US disclosed
US-3952012-A MULTISTAGE MCNEIL LABORATORIES, INCORPORATED (US) 1976-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CXCR2, MMP8, CXCR1 PTGS2 124/4885CXCL8 8/4885AKR1B1 661/4885
US-20110195967-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CXCR2, MMP8, CXCR1 PTGS2 124/4885CXCL8 8/4885AKR1B1 681/4885
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia CXCR2, CXCR1, MMP8 PTGS2 121/4885CXCL8 8/4885AKR1B1 1249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.